Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Autologous CD19 CAR-T”

123 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 123 results

Early research (Phase 1)Looking for participantsNCT07331467
What this trial is testing

Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE

Who this might be right for
Systemic Lupus Erythematosus
Chongqing Precision Biotech Co., Ltd 18
Not applicableLooking for participantsNCT06961669
What this trial is testing

Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma

Who this might be right for
Lymphoblastic LeukemiaRelapsed or Refractory Multiple Myeloma (RRMM)
Anhui Provincial Hospital 18
Early research (Phase 1)Active Not RecruitingNCT05665062
What this trial is testing

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

Who this might be right for
CLL/SLLNHLMantle Cell Lymphoma+4 more
Synthekine 36
Testing effectiveness (Phase 2)Looking for participantsNCT03938987
What this trial is testing

Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
Relapsed Non Hodgkin LymphomaRelapsed Adult ALLRelapsed Pediatric ALL
University of Alberta 63
Very early researchUnknownNCT05239676
What this trial is testing

Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant Lymphoma

Who this might be right for
Lymphoma
Zhejiang University 50
Not applicableLooking for participantsNCT07052565
What this trial is testing

CAR-T Cells Therapy for Patients With Autoimmune Diseases

Who this might be right for
Autoimmune Diseases
Anhui Provincial Hospital 18
Testing effectiveness (Phase 2)Looking for participantsNCT06698484
What this trial is testing

To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)

Who this might be right for
Relapsed/Refractory B- Cell Non-Hodgkin Lymphoma
National University of Malaysia 20
Early research (Phase 1)Looking for participantsNCT06676982
What this trial is testing

Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma

Who this might be right for
Advanced Hepatocellular Carcinoma
Zhejiang University 12
Testing effectiveness (Phase 2)Study completedNCT01865617
What this trial is testing

Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia

Who this might be right for
CD19-Positive Neoplastic Cells PresentRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Chronic Lymphocytic Leukemia+10 more
Fred Hutchinson Cancer Center 204
Testing effectiveness (Phase 2)Looking for participantsNCT05674175
What this trial is testing

Co-administration of CART22-65s and huCART19 for B-ALL

Who this might be right for
B-cell Acute Lymphoblastic LeukemiaB Lineage Lymphoblastic Lymphoma
Stephan Grupp MD PhD 93
Early research (Phase 1)Study completedNCT04488354
What this trial is testing

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

Who this might be right for
Relapsed/Refractory B-cell LymphomasDiffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)+9 more
Calibr, a division of Scripps Research 16
Testing effectiveness (Phase 2)Looking for participantsNCT07523542
What this trial is testing

SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus

Who this might be right for
REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUSLupus Nephritis
Beijing Biotech 24
Testing effectiveness (Phase 2)Looking for participantsNCT06328777
What this trial is testing

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

Who this might be right for
Systemic SclerosisScleroderma
Cabaletta Bio 12
Early research (Phase 1)UnknownNCT03208556
What this trial is testing

Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma

Who this might be right for
Relapsed or Refractory B-cell Lymphoma
Peking University 20
Early research (Phase 1)Looking for participantsNCT07304154
What this trial is testing

A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases

Who this might be right for
Chronic Inflammatory Demyelinating PolyneuropathyMyasthenia GravisMultiple Sclerosis
Kite, A Gilead Company 52
Early research (Phase 1)Active Not RecruitingNCT04049513
What this trial is testing

ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)

Who this might be right for
Lymphomas Non-Hodgkin's B-CellDiffuse Large B-cell Lymphoma (DLBCL)Primary Mediastinal B-cell Lymphoma (PMBCL)+3 more
Malaghan Institute of Medical Research 30
Early research (Phase 1)Looking for participantsNCT05963217
What this trial is testing

Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

Who this might be right for
Relapsed or Refractory CD19+ B-cell LymphomaRelapsed or Refractory Chronic Lymphocytic LeukemiaRelapsed or Refractory Small Lymphocytic Lymphoma
University Health Network, Toronto 19
Testing effectiveness (Phase 2)Looking for participantsNCT06364423
What this trial is testing

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

Who this might be right for
Leukemia, Lymphocytic, Chronic, B-CellB-Lymphocytic Leukemia, ChronicB-Cell Chronic Lymphocytic Leukemia+4 more
National Cancer Institute (NCI) 132
Very early researchEnded earlyNCT06462144
What this trial is testing

IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy

Who this might be right for
Systemic Lupus Erythematosus (SLE)ANCA Associated Vasculitis (AAV)Idiopathic Inflammatory Myopathy (IIM)
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 3
Early research (Phase 1)Study completedNCT02631044
What this trial is testing

Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

Who this might be right for
Non-Hodgkin LymphomaDiffuse Large B Cell LymphomaFollicular Lymphoma+2 more
Juno Therapeutics, a Subsidiary of Celgene 387
Load More Results